博莱霉素
医学
特发性肺纤维化
人性化鼠标
单克隆抗体
耐受性
肺
肺纤维化
纤维化
肺功能测试
免疫学
癌症研究
药理学
抗体
组织谷氨酰胺转胺酶
呼吸道疾病
人肺
病理
单克隆
临床试验
体内
间质性肺病
拉顿
吡非尼酮
作者
Erica Ferrini,Costanza Bonfini,Anna Maria Capelli,Timothy Johnson,Wouter Eijkelkamp,Maurizio Civelli,Gino Villetti,Fabio Stellari
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2026-09-05
卷期号:: PA4369-PA4369
标识
DOI:10.1183/13993003.congress-2026.pa4369
摘要
Zampilimab is a humanized monoclonal antibody that selectively binds human tissue transglutaminase-2 (hTG2), inhibiting its transamidation activity. The compound has recently completed a Phase Ib clinical trial ( NCT05513950 ) in patients with idiopathic pulmonary fibrosis (IPF). To investigate the antifibrotic efficacy of zampilimab, we generated a novel humanized mouse model with ubiquitous expression of human transglutaminase 2 (hTG2). Pulmonary fibrosis was induced in male hTG2 C57BL/6 mice using bleomycin (BLM) via oropharyngeal aspiration on days 0 and 4. Quantitative lung structural and functional changes associated with disease progression, as well as the antifibrotic efficacy of zampilimab, were monitored longitudinally by micro-computed tomography (µCT) on days 7, 14, and 21. As terminal procedure, lung function (flexivent), histology, and hTG2 transamidation activity, were also accessed. Bleomycin administration induced progressive pulmonary fibrosis from days 14 to 21, as indicated by an increase in non-aerated lung regions, a decline in lung ventilation and tidal volume, and enhanced hTG2 transamidation activity within fibrotic areas. Zampilimab treatment markedly attenuated pulmonary fibrosis, as evidenced by micro-CT, showing reduced non-aerated tissue and improved ventilation and tidal volume. This effect was accompanied by a significant decrease in hTG2 transamidation, indicating reduced pulmonary stiffness. The results obtained from a humanized hTG2 mouse model highlight the central role of TG2 in pulmonary fibrosis, indicating that selective inhibition of transamidation activity of hTG2 by zampilimab can significantly improve lung function and micro-CT–derived functional biomarkers. Its favorable tolerability further support the continued development of zampilimab.
科研通智能强力驱动
Strongly Powered by AbleSci AI